On Sept 18, Zymeworks' Unit & Beigene Entered Into Termination Agreement For License And Collaboration Agreement Of Zanidatamab Zovodotin
Portfolio Pulse from Benzinga Newsdesk
Zymeworks' unit and Beigene have entered into a termination agreement for the license and collaboration agreement of Zanidatamab Zovodotin on September 18.
September 21, 2023 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Zymeworks' termination of its collaboration with Beigene could potentially impact its future revenues and growth prospects.
The termination of the collaboration agreement with Beigene could potentially affect Zymeworks' future revenues and growth prospects. This is because the collaboration could have led to the development of new products and revenue streams for Zymeworks. Therefore, the termination could be seen as a negative development for the company.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100